TY - JOUR
T1 - Targeted therapy and handfoot skin reaction in advanced renal cell carcinoma
AU - Yang, Chih Hsun
AU - Chuang, Cheng Keng
AU - Hsieh, Jia Juan
AU - Chang, John Wen Cheng
PY - 2010/5
Y1 - 2010/5
N2 - Importance of the field: Targeted therapy has significantly prolonged the survival of patients with advanced renal cell carcinoma (RCC). As first-line treatment, sunitinib, temsirolimus and bevacizumab plus IFN-α are demonstrated to prolong progression-free survival and/or overall survival. As second-line treatment, sorafenib was active mainly for patients in whom cytokine therapy failed. Recently, second-line treatment with everolimus has been shown to benefit patients progressing through tyrosine kinase inhibitors. Meanwhile, FDA has just approved pazopanib for the treatment of patients with advanced RCC. Various toxicities were associated with these agents. These toxicities were generally well tolerated. However, a high frequency of severe skin and bone marrow toxicities has been reported in Asian countries. Areas covered in this review: We have reviewed the literature of current targeted therapeutic agents and handfoot skin reaction (HFSR) in advanced RCC available in MEDLINE and meeting reports of ASCO, ECCO-ESMO and the 2009 Genitourinary Cancers Symposium. What the reader will gain: Readers will know of the efficacy and safety, including HFSR, of current targeted therapy. Take home message: Careful monitoring and appropriate management of the toxicities, especially HFSR, are needed.
AB - Importance of the field: Targeted therapy has significantly prolonged the survival of patients with advanced renal cell carcinoma (RCC). As first-line treatment, sunitinib, temsirolimus and bevacizumab plus IFN-α are demonstrated to prolong progression-free survival and/or overall survival. As second-line treatment, sorafenib was active mainly for patients in whom cytokine therapy failed. Recently, second-line treatment with everolimus has been shown to benefit patients progressing through tyrosine kinase inhibitors. Meanwhile, FDA has just approved pazopanib for the treatment of patients with advanced RCC. Various toxicities were associated with these agents. These toxicities were generally well tolerated. However, a high frequency of severe skin and bone marrow toxicities has been reported in Asian countries. Areas covered in this review: We have reviewed the literature of current targeted therapeutic agents and handfoot skin reaction (HFSR) in advanced RCC available in MEDLINE and meeting reports of ASCO, ECCO-ESMO and the 2009 Genitourinary Cancers Symposium. What the reader will gain: Readers will know of the efficacy and safety, including HFSR, of current targeted therapy. Take home message: Careful monitoring and appropriate management of the toxicities, especially HFSR, are needed.
KW - Handfoot skin reaction
KW - Renal cell carcinoma
KW - Targeted therapy
KW - Tolerance
UR - http://www.scopus.com/inward/record.url?scp=77951641229&partnerID=8YFLogxK
U2 - 10.1517/14740331003596349
DO - 10.1517/14740331003596349
M3 - 文献综述
C2 - 20113155
AN - SCOPUS:77951641229
SN - 1474-0338
VL - 9
SP - 459
EP - 470
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
IS - 3
ER -